Investigating Plinabulin for Prevention of Chemotherapy-Induced Neutropenia

Investigating Plinabulin for Prevention of Chemotherapy-Induced Neutropenia

Dr. Birnholz discusses updates from a phase 2/3 multi-center trial studying the effects of plinabulin with lead investigator, Dr. Blayney.
  • Overview

    Severe neutropenia is a dangerous potential complication of myelosuppressive chemotherapy, which exposes patients to high risks of infections and can result in death. 

    Dr. Douglas W. Blayney, oncologist and Professor of Medicine at the Cancer Institute of Stanford University School of Medicine, joins host Dr. Matt Birnholz, to discuss a phase 2 of 3 clinical research trial, which is investigating the role of plinabulin for reducing the duration of severe neutropenia in cancer patients undergoing chemotherapy.  

    BeyondSpring is currently identifying sites for enrollment in the Phase 3 clinical trials. These trials are intended for patients who have failed one or more prior treatment regiments including chemotherapy or immunotherapy for advanced (Stage IIIB) or metastatic disease (Stage IV). To inquire about site enrollment, please contact BeyondSpring Pharmaceuticals at


Facebook Comments

Sign-up for the Prova Education newsletters.

Better education for a better you.

* Required